Invivyd, Inc. (NASDAQ:IVVD) Director Sells $41,541.60 in Stock

Invivyd, Inc. (NASDAQ:IVVD) Director Terrance Mcguire sold 86,545 shares of the firm’s stock in a transaction dated Monday, December 30th. The shares were sold at an average price of $0.48, for a total transaction of $41,541.60. Following the completion of the transaction, the director now directly owns 3,170,231 shares in the company, valued at approximately $1,521,710.88. The trade was a 2.66 % decrease in their position. The sale was disclosed in a filing with the SEC, which can be accessed through the SEC website.

Terrance Mcguire also recently made the following trade(s):

• On Thursday, December 26th, Terrance Mcguire sold 83,817 shares of Invivyd stock. The stock was sold at an average price of $0.54, for a total value of $45,261.18.
• On Monday, December 23rd, Terrance Mcguire sold 75,776 shares of Invivyd stock. The shares were sold at an average price of $0.45, for a total value of $34,099.20.
• On Friday, December 20th, Terrance Mcguire sold 119,805 shares of Invivyd stock. The shares were sold at an average price of $0.42, for a total value of $50,318.10.
• On Wednesday, December 18th, Terrance Mcguire sold 74,764 shares of Invivyd stock. The stock was sold at an average price of $0.47, for a total transaction of $35,139.08.
• On Monday, December 16th, Terrance Mcguire sold 65,359 shares of Invivyd stock. The shares were sold at an average price of $0.47, for a total transaction of $30,718.73.
• On Wednesday, December 11th, Terrance Mcguire sold 160,400 shares of Invivyd stock. The stock was sold at an average price of $0.59, for a total transaction of $94,636.00.
• On Monday, December 9th, Terrance Mcguire sold 150,000 shares of Invivyd stock. The stock was sold at an average price of $0.61, for a total transaction of $91,500.00.

Invivyd Price Performance

NASDAQ:IVVD opened at $0.44 on Thursday. The company has a market capitalization of $53.00 million, a P/E ratio of -0.23 and a beta of 0.53. The business has a fifty day simple moving average of $0.70 and a two-hundred day simple moving average of $0.95. Invivyd, Inc. has a 1 year low of $0.40 and a 1 year high of $5.20.

Wall Street Analyst Weigh In

A number of brokerages recently commented on IVVD. EF Hutton Acquisition Co. I raised Invivyd to a “strong-buy” rating in a research report on Wednesday, October 30th. HC Wainwright reduced their price objective on Invivyd from $15.00 to $10.00 and set a “buy” rating for the company in a research note on Wednesday, November 20th. Morgan Stanley lowered their target price on Invivyd from $9.50 to $3.55 and set an “overweight” rating on the stock in a research note on Wednesday, November 20th. Finally, D. Boral Capital restated a “buy” rating and set a $9.00 price target on shares of Invivyd in a research report on Thursday, November 21st. Four analysts have rated the stock with a buy rating and one has assigned a strong buy rating to the company. According to data from MarketBeat.com, the company presently has a consensus rating of “Buy” and a consensus price target of $7.89.

Institutional Investors Weigh In On Invivyd

Several large investors have recently added to or reduced their stakes in the company. XTX Topco Ltd boosted its position in Invivyd by 68.1% during the second quarter. XTX Topco Ltd now owns 37,938 shares of the company’s stock worth $42,000 after purchasing an additional 15,376 shares during the period. Proficio Capital Partners LLC purchased a new stake in shares of Invivyd during the 3rd quarter valued at approximately $27,000. Marshall Wace LLP boosted its holdings in Invivyd by 4.2% in the 2nd quarter. Marshall Wace LLP now owns 786,899 shares of the company’s stock worth $866,000 after buying an additional 31,992 shares during the period. State Street Corp grew its stake in Invivyd by 3.7% in the 3rd quarter. State Street Corp now owns 1,018,640 shares of the company’s stock valued at $1,039,000 after buying an additional 35,904 shares in the last quarter. Finally, Cubist Systematic Strategies LLC raised its holdings in Invivyd by 66.1% during the 2nd quarter. Cubist Systematic Strategies LLC now owns 134,452 shares of the company’s stock valued at $148,000 after acquiring an additional 53,499 shares during the period. Hedge funds and other institutional investors own 70.36% of the company’s stock.

Invivyd Company Profile

Invivyd, Inc, a commercial-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of antibody-based solutions for infectious diseases in the United States. The company developed INVYMAB, a platform that combines viral surveillance and predictive modeling with advanced antibody engineering.